Founded September 2016
Stage Business development
Investor Trendlines Incubators Israel
CEO Amir Marmor
CorAlert is developing an accurate, easy-to-use, noninvasive detection and monitoring device for diagnosing heart failure (HF) in real time.
Left Ventricular End-Diastolic Pressure (LVEDP), the pressure in the left ventricle after it has filled with blood and before it contracts, is an accepted measure to identify patients suffering from HF. In nearly all people with HF, LVEDP is elevated. Unfortunately, measuring LVEDP involves an invasive procedure that is rarely performed today.
CorAlert is developing an accurate, easy-to-use, noninvasive device for early detection and monitoring of HF in real time. CorAlert’s device accurately estimates LVEDP based on analyzing central aortic pressure and measuring heartbeats. The system consists of the CorAlert smart pump placed on the upper arm, a sensor placed on the chest, and CorAlert’s proprietary software for accurate estimates and analysis of LVEDP.
The Company’s method provides a full hemodynamic profile based on three critical measurements:
CorAlert represents a new approach in the practice of cardiology that will significantly improve patient healthcare and reduce hospital costs.
The market seeks a low-cost, noninvasive solution for early detection and monitoring of patients suffering from HF.
See CEO Amir Marmor on ILTV.
Extensive experience in medical device start-ups as software/algorithm engineer
Professor of Medicine and Cardiology Chair, Bar-Ilan University; former Head of Heart Institute, Director of Cardiology Ziv Medical Center, Safed, Israel
Cardiologist, University of California San Francisco (UCSF) Heart and Vascular Center, and Director Mechanical Circulatory Support and Heart Failure Device Program; specializes in treating patients with heart failure and arrhythmias
Extensive experience in investment and business development in high tech; currently, CEO of Prodac Systems
Heart failure (HF) occurs as the heart muscle weakens. As a result, the heart struggles to meet the body’s needs. This condition manifests itself in shortness of breath, fatigue, and sudden weight gain. In its early stages, HF often goes undetected. As HF progresses, however, it may cause pulmonary edema, hospitalization, or death. HF affects 26 million adults worldwide, with more than 5.7 million in the United States. Up to 42% of patients admitted to hospitals with HF die within five years.
Both the mortality rate and high cost of treating HF are due to the difficulty in assessing the patient’s condition in real time, which may result in misdiagnosis.